FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
 
Skip Navigation LinksHome / News / Read News

Print

Tiger Group Accepting Bids for Biotech International’s IP Assets

February 11, 2014, 07:21 AM
Filed Under: Consumer Products

In a press release, Tiger Group’s Remarketing Services Division announced it is now accepting sealed bid offers for intellectual property, inventory and other assets of Biotech International Corporation, including its flagship DermaSilk brand, a leading line of anti-aging and skincare products. The sale is being conducted on behalf of First Niagara Bank NA, the secured creditor for Glastonbury, Conn.-based Biotech International. 

Recognized as one of the Top-10 anti-aging products in the United States, DermaSilk’s products are carried by such top retailers as CVS, Walgreens, Wal-Mart, Rite Aid, Sears and Kroger.

Assets being sold include popular product lines and trademarks for DermaSilk, formulas and customer lists. More than $1 million of finished goods will also be available for sale, along with thousands of units of packaging and displays. The assets are being offered for sale on a turnkey basis or in any combination.  Sealed bids will be accepted through 5:00 p.m. EST, February 19.

“Health and beauty companies, or other businesses with skincare and cosmetic lines will be interested in this unique opportunity for a brand that ranked sixth domestically in a category that includes such names as Oil of Olay, L’Oreal and Neutrogena,” said Andy Babcock, Tiger Group’s Director of Inventory Strategies. “Demand for DermaSilk continues to be robust.”

Tiger Group provides asset valuation, advisory and disposition services to a broad range of retail, wholesale, and industrial clients. With over 40 years of experience and significant financial backing, Tiger offers a uniquely nimble combination of expertise, innovation and financial resources to drive results. Tiger operates main offices in Boston, Los Angeles and New York.





Week's News



Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.